IMMU earnings call for the period ending December 31, 2018.
News & Analysis: Immunomedics
The FDA sent the biotech back to the drawing board.
A handful of updates heading into a critical regulatory review date had investors reconsidering a healthy market cap.
The company is inching closer to commercializing its first major product.
It was off to the races earlier today following compelling data on Immunomedics' lead drug.
The release of upbeat clinical data from an important phase 2 trial causes traders to cheer.
A new CEO has the biotech's investors excited.
The biopharma appears to be riding higher in the wake of the Kite Pharma mega deal.
Optimism surrounding its terminated licensing pact with Seattle Genetics sends shares soaring for a second straight day.
The biotech has a new plan that investors seem to like.
Sometimes it's what a company doesn't do that matters.